Clinical Trial Update: A Study of GR1803 in Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

Ongoing clinical trial update for GR1803 in systemic lupus erythematosus, spanning Phase 1 and Phase 2, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GR1803

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Systemic Lupus Erthematosus, Auto Immune Disease | Phase 1, Phase 2 | Status: RECRUITING